You are here

  • Home
  • Archive
  • Volume 93, Issue 3
  • Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study

Article metrics

Article menu
Migraine
Original research
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study

 

Online download statistics by month:

Online download statistics by month: November 2021 to October 2024

AbstractFullPdf
Nov 202118518533
Dec 2021953936204
Jan 202253854191
Feb 2022724743197
Mar 2022548560154
Apr 202236136983
May 202217517065
Jun 202216416551
Jul 202213212630
Aug 202212511829
Sep 202210110545
Oct 202217416845
Nov 202214414147
Dec 202214714123
Jan 202311211652
Feb 202313413434
Mar 202312913126
Apr 2023747236
May 2023626227
Jun 2023605821
Jul 2023898121
Aug 2023706619
Sep 2023848619
Oct 2023929422
Nov 202312312128
Dec 202313110916
Jan 2024534021
Feb 20241039218
Mar 202410410079
Apr 2024959444
May 2024888240
Jun 2024939036
Jul 2024878341
Aug 2024544423
Sep 2024716831
Oct 2024747334
Total645363641785